Anzeige
Meldung des Tages: Gold im Fokus: Warum diese milliardenschwere Goldaktie vom aktuellen Goldumfeld profitieren könnte

Aethlon Medical Aktie News

Aktie
WKN:  A41NJ5 ISIN:  US00808Y6041 US-Symbol:  AEMD Branche:  Biotechnologie Land:  USA
2,245 $
-0,095 $
-4,06%
1,9044 € 04.02.26
Depot/Watchlist
Marktkapitalisierung *
437,11 Tsd. €
Streubesitz
-
KGV
-
Index-Zuordnung
-

Aethlon Medical News

04.02.26 - PR Newswire
Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2026
Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2026 PR Newswire
05.12.25 - PR Newswire
Aethlon Medical Announces Pricing of a Private Placement and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $3.3 Million
Aethlon Medical Announces Pricing of a Private Placement and Warrant Inducement, Priced At-​The-Market for Aggregate Gross Proceeds of $3.3 Million PR Newswire
02.12.25 - PR Newswire
Aethlon Medical Announces Publication of Preclinical Data Showing That the GNA Affinity Resin in the Hemopurifier® Binds to Extracellular Vesicles in Long COVID patient samples and Decreases Inflammatory microRNAs
Aethlon Medical Announces Publication of Preclinical Data Showing That the GNA Affinity Resin in the Hemopurifier® Binds to Extracellular Vesicles in Long COVID patient samples ...
12.11.25 - PR Newswire
Aethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate Update
Aethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate Update PR Newswire
07.11.25 - PR Newswire
Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 12, 2025
Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 12, 2025 PR Newswire
07.10.25 - PR Newswire
Aethlon Medical's Hemopurifier® shows Changes in Extracellular Vesicles, Extracellular MicroRNAs, and T Cell Numbers in Australian Oncology Clinical Trial
Aethlon Medical's Hemopurifier® shows Changes in Extracellular Vesicles, Extracellular MicroRNAs, and T Cell Numbers in Australian Oncology Clinical Trial PR Newswire
04.09.25 - PR Newswire
Aethlon Medical Announces Pricing of $4.5 Million Public Offering
Aethlon Medical Announces Pricing of $4.5 Million Public Offering PR Newswire
03.09.25 - PR Newswire
Aethlon Medical Announces Issuance of Hemopurifier® Patents for the Treatment of Long COVID and COVID-19-associated Coagulopathy (CAC)
Aethlon Medical Announces Issuance of Hemopurifier® Patents for the Treatment of Long COVID and COVID-19-associated Coagulopathy (CAC) PR Newswire
13.08.25 - PR Newswire
Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2025, and Provides Corporate Update
Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2025, and Provides Corporate Update PR Newswire
05.08.25 - PR Newswire
Aethlon Medical to Release Fiscal First Quarter Financial Results and Host Conference Call on August 13, 2025
Aethlon Medical to Release Fiscal First Quarter Financial Results and Host Conference Call on August 13, 2025 PR Newswire
15.07.25 - PR Newswire
Aethlon Medical, Inc. Announces Positive Data Safety Monitoring Board Review and Recommendation to Advance to Next Clinical Trial Cohort
Aethlon Medical, Inc. Announces Positive Data Safety Monitoring Board Review and Recommendation to Advance to Next Clinical Trial Cohort PR Newswire
26.06.25 - PR Newswire
Aethlon Medical Announces Financial Results for the Fiscal Fourth Quarter Ended March 31, 2025, and Provides Corporate Update
Aethlon Medical Announces Financial Results for the Fiscal Fourth Quarter Ended March 31, 2025, and Provides Corporate Update PR Newswire
20.06.25 - PR Newswire
Aethlon Medical to Release Fiscal Fourth Quarter Financial Results and Host Conference Call on June 26, 2025
Aethlon Medical to Release Fiscal Fourth Quarter Financial Results and Host Conference Call on June 26, 2025 PR Newswire
18.06.25 - PR Newswire
Aethlon Medical Treats Second Patient in Australian Hemopurifier® Cancer Trial
Aethlon Medical Treats Second Patient in Australian Hemopurifier® Cancer Trial PR Newswire
09.06.25 - PR Newswire
Aethlon Medical to Present New Pre-Clinical Data at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes
Aethlon Medical to Present New Pre-​Clinical Data at the Keystone Symposium on Long COVID and Other Post-​Acute Infection Syndromes PR Newswire
14.05.25 - PR Newswire
Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Platelet-Derived Extracellular Vesicles from Plasma
Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Platelet-​Derived Extracellular Vesicles from Plasma PR Newswire
10.03.25 - PR Newswire
Aethlon Medical Publishes Preclinical Data on the Hemopurifier® in Transplant Immunology Journal
Aethlon Medical Publishes Preclinical Data on the Hemopurifier® in Transplant Immunology Journal PR Newswire
13.02.25 - PR Newswire
Aethlon Medical to Present at the Emerging Growth Conference on February 19, 2025
Aethlon Medical to Present at the Emerging Growth Conference on February 19, 2025 PR Newswire
12.02.25 - PR Newswire
Aethlon Medical Announces Financial Results for the Fiscal Third Quarter Ended December 31, 2024 and Provides Corporate Update
Aethlon Medical Announces Financial Results for the Fiscal Third Quarter Ended December 31, 2024 and Provides Corporate Update PR Newswire
05.02.25 - PR Newswire
Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2025
Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2025 PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr +5,17%
Technical Trading: Pfund Short im Februar
GBP/USD Short Typ: Turbo Open End WKN: VH3A2E Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »